News and Trends 9 Nov 2016 Up, up and away! CureVac’s money pile now Totals €325M CureVac has raised an additional €27M ($29.5M) that will help the company keep on its track to be the first one to launch a mRNA therapy, a technology that can revolutionize how drugs are designed. CureVac is a German company in the billion-euro biotech club at the forefront of messenger RNA (mRNA) therapies, a technology that […] November 9, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Nov 2016 These companies want to use Stem Cells to improve Drug Safety Axiogenesis and Metrion Biosciences will use stem cells to improve preclinical neurotoxicity and cardiac safety testing, a feat that can significantly reduce the time and cost of drug discovery and clinical development. Axiogenesis is a Biotech from Cologne, Germany, that develops cell lines derived from induced pluripotent stem cells (iPSCs) for preclinical applications. The company […] November 8, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2016 Green Light for Genfit to Tackle another Liver Disease The FDA has cleared Genfit’s IND application to treat a second liver disease with a big unmet clinical need. With this new step forward, the company gets even closer to become the leader in liver disease treatments. After a very successful fundraising last week, Genfit is kicking off the week with good news from the […] November 7, 2016 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2016 Results from 45% of Clinical Trials are kept Secret A new transparency study has identified Sanofi, Novartis and GSK as the companies that keep the most clinical trial results unreported. TrialsTracker is a tool developed at the University of Oxford that automatically rates transparency on clinical trials by checking if there are results available in clinicaltrials.gov and PubMed. The results: globally, 45% of data on […] November 7, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Nov 2016 The Mind Behind the Artificial Pancreas that Could Change the Lives of Diabetics We had the opportunity to talk with Roman Hovorka, from The University of Cambridge, who’s working on a revolutionary medical device that can automatically improve glucose levels in people with type 1 diabetes. An artificial pancreas is a device that measures glucose levels and responds by injecting the right amount of insulin required at any […] November 7, 2016 - 5 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Nov 2016 Would you Taste this Gene-Edited Dinner? Genetic engineering can make food healthier, improve nutrition and reduce environmental impact. To demonstrate its potential, Cellectis hosted a dinner featuring futuristic food technology. Cellectis is a French company that develops immuno-oncology therapies and became famous last year when its CAR-T treatment saved a 1-year old girl from leukemia. Its gene-editing TALEN technology is also used by […] November 5, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 4 Nov 2016 This Company has developed a Personalized App to Fight Cancer We say goodbye to the good weather in Spain and cross the Pyrenees to visit Charleroi, an industrial city south of Brussels. There, we find OncoDNA, a young company striving to change the oncology field using DNA. City: Charleroi, Belgium Founded: 2012 Employees: 11 – 50 Financial data: €7.7M raised in September to expand into the global market Mission: […] November 4, 2016 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 2 Nov 2016 Antibody Therapies are here to Revolutionize Dermatology Leo Pharma is offering MorphoSys no less than €111.5M per antibody treatment with applications in dermatology, a very profitable field with big unmet needs. New cancer therapies might also arise from this exciting partnership! MorphoSys is a leader in the development of therapeutic antibodies with top-level partners like Novartis, Roche, Pfizer, Bayer, GSK, Galapagos […] November 2, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 1 Nov 2016 Novo Nordisk pressured into Dropping Needle-Free Oral Insulin Needle-free diabetes will have to wait: payers are pressuring pharma to provide lower medication prices, and Novo Nordisk has responded by redirecting its R&D strategy into more innovative research. Despite its position as a world leader in diabetes, Novo Nordisk seems to be hitting a rough patch: the big pharma is reducing its profit and […] November 1, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2016 Shooting for the Moon: German Biotech Acquired for a Record €1.3B Ganymed Pharmaceuticals is the protagonist of Germany’s biggest biotech deal ever; Astellas Pharma has offered up to €1.3B to get hold of Ganymed’s first-in-class cancer antibody technology. Ganymed Pharmaceuticals develops first-in-class antibody therapies for cancer. Its technology seems to be so promising that the Japanese Astellas Pharma has decided to acquire it in what will be the […] October 31, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 31 Oct 2016 This might be the First 3-in-1 Therapy for Highly Metastatic Cancer Amcure’s candidate for highly metastatic epithelial cancers is about to start clinical trials. The compound can shut down three oncological pathways simultaneously through a single molecular target. Amcure is a spin-off from the Karlsruhe Institute of Technology in Germany, established in 2012. The company develops treatments for highly metastatic forms of cancer using peptide-based compounds targeting angiogenesis. It […] October 31, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 Oct 2016 TCR and Checkpoint inhibitors: A Match made in Heaven for Blood Cancer Adaptimmune and MSD are collaborating to test a therapy for multiple myeloma that combines some of the most promising technologies in immuno-oncology: TCR and checkpoint inhibitors. Adaptimmune is an immuno-oncology billion-euro Biotech from the British Golden Triangle. Despite some trouble with the FDA recently, the company continues to forge ahead with its promising TCR technology. Now, […] October 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email